Nasdaq announced on September 17, 2026, that it will file a Form 25 with the SEC to delist Aditxt, Inc.'s common stock. The delisting becomes effective ten days after the Form 25 filing. Trading was previously suspended on June 25, 2026, following a denial of the company's request to continue listing by the Nasdaq Hearings Panel. The company's shares are currently quoted on the OTC Market. Aditxt, Inc. operates in the biotechnology industry, focusing on developing therapies for cancer and other diseases.
